FMP

FMP

Enter

REGN - Regeneron Pharm...

photo-url-https://images.financialmodelingprep.com/symbol/REGN.png

Regeneron Pharmaceuticals, Inc.

REGN

NASDAQ

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

590 USD

-8.76 (-1.48%)

Historical Prices

From:

To:

580.59582585588591593.9109:30 AM09:50 AM10:10 AM10:30 AM10:50 AM11:10 AM11:31 AM11:51 AM12:11 PM12:31 PM12:51 PM01:12 PM01:32 PM01:52 PM02:12 PM02:32 PM02:52 PM03:12 PM03:32 PM03:52 PM

About

ceo

Dr. Leonard S. Schleifer M.D., Ph.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carci...

CIK

0000872589

ISIN

US75886F1075

CUSIP

75886F107

Address

777 Old Saw Mill River Road

Phone

914 847 7000

Country

US

Employee

15,158

IPO Date

Apr 2, 1991

Financial Statement

01B2B3B4B2024 Q12024 Q22024 Q32024 Q42025 Q1RevenueNet Income

Earnings

024681012142023 Q22023 Q32023 Q42024 Q12024 Q22024 Q32024 Q42025 Q1EPS Consensus

REGN Financial Summary

CIK

0000872589

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

75886F107

ISIN

US75886F1075

Country

US

Price

590

Beta

0.43

Volume Avg.

1.06M

Market Cap

63.1B

Shares

-

52-Week

525.99-1211.2

DCF

1.84k

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

15

P/B

-

Website

https://www.regeneron.com

Upgrades and Downgrades

Rating Distribution

Buy1

Hold0

Sell0

TheFly

10 days ago
Apr 22, 2025

Neutral

Overweight

Latest REGN News

Gordon Thompson

Nov 14, 2024

Citigroup Initiates Coverage on Regeneron Pharmaceuticals wi...

On November 13, 2024, Citigroup initiated coverage on Regeneron Pharmaceuticals (NASDAQ:REGN) with a "Neutral" rating. Regeneron, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for serious diseases. It competes with other pharmaceutical giants like Amgen and Biogen. At the time of Citigroup's announcement, Regeneron's stock price was $804.33, as reported by StreetInsider. Citi set a price target of $895 for Regeneron, indicating potential grow...

Zacks Investment Research

Aug 21, 2024

Regeneron (REGN) Gets CRL From FDA for Multiple Myeloma Drug

Regeneron (REGN) suffers a delay in obtaining FDA approval of linvoseltamab for the treatment of relapsed/refractory multiple myeloma.

Reuters

Aug 20, 2024

US FDA declines to approve Regeneron's blood cancer therapy

The U.S. Food and Drug Administration declined to approve Regeneron's therapy for a common form of blood cancer, the company said on Tuesday.

Stockmarketcom

Aug 13, 2024

2 Biotech Stocks To Watch In August 2024

Biotech stocks to keep on your radar this month.

InvestorPlace

Aug 13, 2024

7 Stocks That Usually Benefit From a Recession

As the dark clouds of a potential recession loom on the horizon, investors are scrambling to find safe havens for their hard-earned money. While it's true that most stocks tend to suffer during economic downturns, there are always a few outliers that manage to defy the odds and emerge stronger than ever.

InvestorPlace

Aug 13, 2024

3 Biotech Stocks Poised for a Comeback After Last Week's Mar...

Due to their sometimes speculative nature, biotech stocks are especially sensitive to broader market corrections like the one experienced last week. This can be exceptionally stressful for investors, especially those who bought into biotech stocks at overbought points in the stocks' trading cycle.

Zacks Investment Research

Aug 9, 2024

HRMY vs. REGN: Which Stock Is the Better Value Option?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN). But which of these two stocks presents investors with the better value opportunity right now?

InvestorPlace

Aug 8, 2024

3 Biotech Stocks With Promising Drug Pipelines: August 2024

Investing in biotech stocks with promising pipelines has to be the most exciting area of the market. A successful drug approval can not only unveil a blockbuster treatment worth billions of dollars, but it can literally change people's lives for the better.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep